HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HUTCHMED (China) Limited (NASDAQ: HCM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.